The The Drug Cell consortium, led by the French Blood Establishment (EFS), GPI, MGA Technologies, and the AFM-Téléthon Stem Cell Research Center, has secured a record-breaking €152 million funding from the European Union.
The goal: to build a modular and scalable cell therapy manufacturing plant in France by 2031.
Bringing together academic and industrial leaders, including Carroucell and EVerZom, this initiative aims to establish a sovereign European production capability, a field still largely dominated by the U.S. and Asia.
As Hervé de Malliard, CEO of MGA Technologies, states: “Our goal is to democratize access to these costly treatments by automating processes and making production viable in Europe.”
A significant leap forward for innovation and European health independence!
In the Same Category
Jean-Noël Barrot at Maison MGA
Industry is a matter of sovereignty. We were delighted to welcome the Minister for Foreign Affairs, Jean-Noël Barrot, to the Maison MGA in Civrieux d’Azergues today. The visit centred on a key issue: how can France remain a major industrial nation in an increasingly...
Jean-Noël Barrot visits Maison MGA: a tribute to French industrial expertise
On Friday, June 5, 2026, we had the pleasure of welcoming Jean-Noël Barrot, Minister for Europe and Foreign Affairs, to our Civrieux-d’Azergues site as part of his visit to the Lyon area focused on major industrial, technological, and healthcare challenges. This visit...